ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1380

Rapid, Clinically Meaningful Pain Improvements Are Associated with Improvements in Other Patient-Reported Outcomes in RA Patients Treated with Upadacitinib

Manish Jain1, Arthur Kavanaugh2, Angela Crowley3, Avani Joshi4, Patrick Zueger5, Diane Caballero6, Andrew Garrison6 and Peter C. Taylor7, 1Endeavor Health Swedish Hospital and Captain James A, Chicago, IL, 2University of California San Diego, La Jolla, CA, 3Illinois Bone and Joint Institute, Hinsdale Orthopaedics, Hinsdale, IL, 4AbbVie, North Chicago, IL, 5AbbVie Inc, North Chicago, IL, 6AbbVie Inc., North Chicago, IL, 7University of Oxford, Oxford, United Kingdom

Meeting: ACR Convergence 2024

Keywords: clinical trial, pain, Patient reported outcomes, rheumatoid arthritis, SF36

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: RA – Treatment Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Pain is a crucial symptom for patients with RA; early and effective treatment can help alleviate it.1 In this post hoc analysis, we investigated if clinically meaningful pain improvements were associated with greater improvements in other patient-reported outcomes (PROs) in patients with inadequate response (IR) to MTX or biologic DMARDs (bDMARDs), following treatment with upadacitinib 15 mg (UPA15), an oral JAK inhibitor.

Methods: MTX-IR (SELECT-COMPARE, N=651) and bDMARD-IR patients (SELECT-BEYOND, N=165 and SELECT-CHOICE, N=303) treated with UPA15 were evaluated separately.2,3,4 Proportions of patients achieving clinically meaningful improvement in Patient’s Global Assessment of pain (visual analog scale < 40/100 and ≥20-point improvement from baseline5) were calculated by observed case analysis through wk 24 (bDMARD-IR) or wk 26 (MTX-IR). Patients were stratified by achievement of clinically meaningful pain improvement at two separate timepoints: wk 2 and wk 24 (bDMARD-IR) or wk 26 (MTX-IR). Proportions of patients in each group that achieved minimum clinically important difference (MCID) in HAQ-DI (≥0.22 decrease), FACIT-Fatigue (≥4 increase; MTX-IR only), SF-36 physical component summary (SF-36 PCS, ≥2.5 increase), SF-36 mental component summary (≥2.5 increase), and EuroQol 5 Dimension 5 Level (≥0.05 increase) at wk 24/26 were calculated with nonresponder imputation. Between group differences in the proportion of MCID achievement for each PRO were calculated with nominal P values generated by Chi-square test.

Results: Pain improved rapidly with UPA15 treatment; 23% of bDMARD-IR and 24% of MTX-IR patients achieved clinically meaningful pain improvement at wk 2 (Figure 1). Pain improvement increased over time; 59% of bDMARD-IR and 71% of MTX-IR patients achieved clinically meaningful pain improvement by wk 24/26. In patients who achieved clinically meaningful pain improvement by wk 2, 83% of bDMARD-IR and 90% of MTX-IR patients maintained the response at wk 24/26. For bDMARD-IR patients who achieved meaningful pain improvement at wk 2 compared to those who did not, a larger proportion of patients reported MCID in HAQ-DI and SF-36 PCS at wk 24 (Figure 2). For MTX-IR patients who achieved meaningful pain improvement at wk 2 compared to those who did not, a greater proportion of patients reported MCID in all PROs at wk 26. For both bDMARD-IR and MTX-IR patients who achieved meaningful pain improvement at wk 24/26 compared to those who did not, a larger proportion of patients reported MCID in all PROs at wk 24/26 (Figure 3).

Conclusion: Clinically meaningful pain improvements, as early as wk 2, with UPA15 treatment were associated with more patients reporting achievement of MCID in PROs measuring physical function, fatigue, mental health, and health-related quality of life. Overall, these results suggest that effective treatment of pain is strongly correlated with meaningful improvements in other PROs in RA.

 

1. Taylor PC. Lancet Rheumatol. 2023;5(6):e351-60.
2. Fleischmann R, et al. Arthritis Rheumatol. 2019;71(11):1788-00.
3. Genovese MC, et al. Lancet. 2022;391(10139):2513-24.
4. Rubbert-Roth A, et al. NEJM. 2020;383(16):1511-21.
5. Tubach F, et al. Arthritis Care Res. 2012;64(11):1699-07.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: M. Jain: AbbVie/Abbott, 2, 5, 6, Amgen, 2, 5, 6, Anaptys Bio, 2, 5, 6, AstraZeneca, 2, 5, 6, Bristol-Myers Squibb(BMS), 2, 5, 6, Celgene, 2, 5, 6, Eli Lilly, 2, 5, 6, Horizon, 2, 5, 6, Janssen, 2, 5, 6, Kolon TissueGene, 2, 5, 6, LG-Chem, 2, 5, 6, Merck/MSD, 2, 5, 6, Moderna, 2, 5, 6, NIH, 2, 5, 6, Novartis, 2, 5, 6, Olatec, 2, 5, 6, Pfizer, 2, 5, 6, Selecta, 2, 5, 6, Shionogi, 2, 5, 6; A. Kavanaugh: AbbVie, 2, Amgen, 2, BMS, 2, Janssen, 2, MoonLake Immunotherapeutics, 2, Novartis, 2, Pfizer, 2, Takeda, 2, UCB, 2, 5; A. Crowley: AbbVie/Abbott, 2, 5, 6, Amgen, 2, 5, 6, Aqtual, 2, 5, 6, Eli Lilly, 5, Exagen, 2, 5, 6, GlaxoSmithKlein(GSK), 2, 5, 6, Horizon, 2, 5, 6, Janssen, 2, 5, 6, Kiowa Kirin, 2, 5, 6, Novartis, 2, 5, Scipher Medicine, 2, 5, 6, SetPoint Medical, 2, 5, 6, SunPharma, 2, 5, 6, UCB, 2, 6; A. Joshi: AbbVie, 3, 11; P. Zueger: AbbVie, 3, 11; D. Caballero: AbbVie/Abbott, 3, 11; A. Garrison: AbbVie/Abbott, 3; P. Taylor: AbbVie, 2, Acelyrin Inc., 2, Biogen, 2, Eli Lilly, 2, Fresenius, 2, Galapagos, 2, 12, Participation on a Data Safety Monitoring Board/Advisory Board, Gilead, 2, GSK, 2, Immunovant, 12, Participation on a Data Safety Monitoring Board/Advisory Board, Janssen, 2, Kymab, 12, Participation on a Data Safety Monitoring Board/Advisory Board, Nordic Pharma, 2, Pfizer, 2, Sanofi, 12, Participation on a Data Safety Monitoring Board/Advisory Board, UCB Pharma, 2.

To cite this abstract in AMA style:

Jain M, Kavanaugh A, Crowley A, Joshi A, Zueger P, Caballero D, Garrison A, Taylor P. Rapid, Clinically Meaningful Pain Improvements Are Associated with Improvements in Other Patient-Reported Outcomes in RA Patients Treated with Upadacitinib [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/rapid-clinically-meaningful-pain-improvements-are-associated-with-improvements-in-other-patient-reported-outcomes-in-ra-patients-treated-with-upadacitinib/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rapid-clinically-meaningful-pain-improvements-are-associated-with-improvements-in-other-patient-reported-outcomes-in-ra-patients-treated-with-upadacitinib/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology